What is Nucleix?
Nucleix is a liquid biopsy company dedicated to advancing cancer treatment by enabling earlier disease detection. Utilizing next-generation sequencing (NGS) and PCR-based epigenetics, the company's proprietary testing approach employs methylation-based identification for the early detection of both initial and recurring cancers. The non-invasive EpiCheck® platform is designed to deliver highly accurate and sensitive results, offering a convenient testing option for patients and the healthcare system. Nucleix is actively building an EpiCheck franchise, starting with its Bladder EpiCheck® testing kit, which is marketed in Europe for bladder cancer recurrence. The company is also progressing with a Lung EpiCheck test for high-risk individuals and developing additional tests for other high-risk diseases.
How much funding has Nucleix raised?
Nucleix has raised a total of $85M across 4 funding rounds:
Unspecified
$5M
Unspecified
$3M
Other Financing Round
$55M
Other Financing Round
$22M
Unspecified (2014): $5M with participation from OrbiMed Advisors LLC
Unspecified (2016): $3M led by Aurum and OrbiMed Israel Partners
Other Financing Round (2021): $55M supported by Lilly Asia Ventures, DSC Investment, LYFE Capital, OrbiMed, Aurum Ventures Private, RA Capital Management, MILFAM, BlackRock, OCI Bio Investments, and Zohar Zisapel
Other Financing Round (2022): $22M featuring Sands Capital
Key Investors in Nucleix
OrbiMed Advisors LLC
OrbiMed Advisors LLC is a specialized investment firm deeply focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services. They support companies at various development stages, leveraging extensive life sciences and healthcare business expertise.
Sands Capital
Sands Capital Management, established in 1992, is an investment firm that manages equity mutual funds and invests in public equity markets, indicating a broad investment strategy within the equity landscape.
Lilly Asia Ventures
Lilly Asia Ventures is a prominent biomedical venture capital firm dedicated to partnering with entrepreneurs to build companies that develop breakthrough products for treating diseases and improving human health.
What's next for Nucleix?
The substantial enterprise-level funding, culminating in the recent major strategic investment, positions Nucleix for significant growth and market penetration. This capital infusion is anticipated to fuel the commercialization of its Lung EpiCheck test and the development of further diagnostic solutions for other critical diseases. Nucleix's strategic focus on expanding its EpiCheck franchise, coupled with its pioneering epigenetic technology, suggests a trajectory aimed at becoming a leader in early cancer detection. The company's ability to attract substantial backing from prominent healthcare investors highlights confidence in its innovative approach and its potential to transform patient care.
See full Nucleix company page
